October 19, 2023
Semaglutide statement and peptide brief updated
In light of recent developments, we’ve updated our official statement on shortage drug compounding and semaglutide, as well as our Prescriber Brief on peptide compounding.
October 19, 2023
Judge throws out one Novo lawsuit
Last week, a Florida District Court judge dismissed Novo Nordisk’s lawsuit against Brooksville Pharmacy, one of the four APC members the drugmaker sued back in June over semaglutide compounding in shortage.
October 19, 2023
New PFM benefit: Best pricing from Capital Drug
APC has leveraged the strength of our large number of Pharmacy-Facility Members to strike a deal with Capital Drug on finished-form drugs.
October 19, 2023
FDA warns on compounded ketamine, lack of monitoring
FDA this week issued a statement warning of potential risks associated with compounded ketamine, including oral formulations, for treatment of psychiatric disorders.
October 6, 2023
Keeping prescribers in the know
The providers you work with may be smart cookies, but they don’t always know compounding. Providers need to know about those issues, and it’s up to you to keep them informed.
October 6, 2023
Time to vote in APC Board elections
Voting is now open for seats on the 2024 APC Board of Directors.
October 6, 2023
Big thanks to CompPAC investors
CompPAC is the way APC supports members of Congress who think like you do about pharmacy compounding. And where does CompPAC get its funding? From compounders like you.
October 6, 2023
Licensed in California? You’ll want to see this
APC staff has prepared a comparison document illuminating the differences between the new USP Chapter <797> on sterile compounding that takes effect November 1 and proposed regulation from the California Board of Pharmacy.
October 6, 2023
Senators to FDA: Preserve access to cBHT
Five U.S. Senators have written to the FDA urging that the agency assure continued patient access to compounded hormones for patients.
October 6, 2023
FDA puts some peptides off-limits
Last Friday, the FDA announced that it has updated the list of bulk drug substances nominated for use under section 503A.
